Tranylcypromine 10mg tablets

Ülke: Birleşik Krallık

Dil: İngilizce

Kaynak: MHRA (Medicines & Healthcare Products Regulatory Agency)

Aktif bileşen:

Tranylcypromine sulfate

Mevcut itibaren:

DE Pharmaceuticals

ATC kodu:

N06AF04

INN (International Adı):

Tranylcypromine sulfate

Doz:

10mg

Farmasötik formu:

Oral tablet

Uygulama yolu:

Oral

Sınıf:

No Controlled Drug Status

Reçete türü:

Valid as a prescribable product

Ürün özeti:

BNF: 04030200

Bilgilendirme broşürü

PACKAGE LEAFLET: INFORMATION FOR THE PATIENT
TRANYLCYPROMINE 10MG TABLETS
(tranylcypromine sulphate)
The name of your medicine is Tranylcypromine 10mg Tablets but will be
referred to as Tranylcypromine Tablets throughout this leaflet.
WHAT IS IN THIS LEAFLET:
1. What Tranylcypromine Tablets are and what they are used for
2. What you need to know before you take Tranylcypromine Tablets
3. How to take Tranylcypromine Tablets
4. Possible side effects
5. How to store Tranylcypromine Tablets
6. Contents of the pack and other information
1. WHAT TRANYLCYPROMINE TABLETS ARE AND WHAT THEY ARE USED FOR
Tranylcypromine Tablets contains the active substance tranylcypromine
which belongs to a group of antidepressant medicines known as
monoamine oxidase inhibitors (MAOIs). It works by stopping the
breakdown of two substances in the brain called serotonin and
noradrenaline. Your medicine should help bring these substances back
to normal levels.
This medicine is used to treat moderate to severe depression in
adults. It
can also help you if you are having feelings of fear (phobia) which
sometimes occurs in depression. This medicine is often used when
other types of antidepressant medicines have not worked.
2. WHAT YOU NEED TO KNOW BEFORE YOU TAKE TRANYLCYPROMINE TABLETS
DO NOT TAKE TRANYLCYPROMINE TABLETS IF:
•
you are allergic to tranylcypromine or any of the other ingredients of
this medicine (listed in section 6)
•
you are taking other MAOIs or have taken other MAOIs within the
last two weeks
•
you have taken clomipramine or imipramine within the last three
weeks or are planning to take them within the next three weeks
•
you suffer from porphyria (which is an inherited disease affecting
the nervous system and skin)
•
you have severe heart disease or any disease of the blood vessels
of the brain
•
you have pheochromocytoma which is a tumour of the adrenal
glands (glands near the kidneys) causing high blood pressure
•
you have been diagnosed with an overactive thyroid gland (a gland
in the neck)
•
you have known

Ürün özellikleri

SUMMARY OF PRODUCT CHARACTERISTICS
1
NAME OF THE MEDICINAL PRODUCT
Parnate 10mg Tablets
Tranylcypromine 10mg Tablets
2
QUALITATIVE AND QUANTITATIVE COMPOSITION
Each tablet contains tranylcypromine sulfate equivalent to 10mg of
tranylcypromine base.
3
PHARMACEUTICAL FORM
Coated tablet.
Geranium red coloured, bi-convex, sugar-coated tablets.
4
CLINICAL PARTICULARS
4.1
THERAPEUTIC INDICATIONS
Tranylcypromine is a non-hydrazine monoamine oxidase inhibitor for the
treatment
of
symptoms
of
depressive
illness
especially
where
phobic
symptoms are present or where treatment with other types of
anti-depressants
has failed. It is not recommended for mild depressive states resulting
from
temporary situational difficulties.
4.2
POSOLOGY AND METHOD OF ADMINISTRATION
Tranylcypromine
10mg
Tablets/
Parnate
10mg
Tablets
are
for
oral
administration only.
Posology
ADULTS
Initially, 1 tablet morning and afternoon. If the response is not
adequate after
the first week add a further tablet at midday, and continue for at
least a week.
A dosage of 3 tablets a day should only be exceeded with caution. When
a
satisfactory
response
has
been
obtained,
dosage
may
be
reduced
to
maintenance level often of 1 tablet a day.
When given with a tranquillizer, the dosage of `parnate' is not
affected when
given concurrently with electroconvulsive therapy; the usual dosage is
1 tablet
twice a day during the series and 1 tablet a day afterwards as
maintenance
therapy.
Older people (over 65 years):
Use with great caution and at a lower dosage.
Paediatric population
Tranylcypromine is not indicated for children under 18 years of age.
Method of administration
Tablets should be swallowed whole with a glass of water.
4.3 CONTRAINDICATIONS
Hypersensitivity to the active substance or to any of the excipients
listed in
section 6.1.
Do not give tranylcypromine until at least two weeks after stopping
treatment
with other MAOIs.
Allow
3
weeks
to
elapse
after
stopping
tranylcypromine
before
starting
clomipramine or imipramine.
Tranylcypromine should not be taken by p